REG - OptiBiotix Health - Issue of Options

OptiBiotix HealthAnnouncement

20/12/2024 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241220:nRST9600Qa&default-theme=true

RNS Number : 9600Q  OptiBiotix Health PLC  20 December 2024

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Issue of Options and Related Party Transaction

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces that, the Company has issued 6,099,135 options over new ordinary
shares with an exercise price of 16 pence per share ("New Options") to Stephen
O'Hara, CEO of the Company. The New Options expire on 17 December 2034 and
vest on the first anniversary of the options being granted being 17 December
2025.

 

The issue of the New Options follows the expiration of 6,099,135 options over
new ordinary shares with an exercise price of 8 pence per share, granted to
Stephen O'Hara, which expired in September 2024.

 

 

 

Related Party Transaction

 

The issuance of the New Options to Stephen O'Hara ("Transaction") is a related
party transaction pursuant to Rule 13 of the AIM Rules.

 

The directors of the Company independent of the Transaction, having consulted
with the Company's nominated adviser, Cairn Financial Advisers LLP, consider
the terms of the Transaction to be fair and reasonable insofar as the
Company's shareholders are concerned.

 

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Joint Broker)         Tel: 020 7220 9797
 Duncan Vasey/ Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Stephen O'Hara
 2   Reason for notification
 a.  Position/Status                                              Director
 b.  Initial notification/                                        Initial Notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         OptiBiotix Health Plc
 b.  LEI                                                          213800UKYQFT941QHS14
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Options over new ordinary shares of 2p each

Identification Code

                                                                  ISIN: GB00BP0RTP38
 b.  Nature of the transaction                                    Issue of options pursuant to the New Options

 c.  Price(s) and volume(s)
                                                                               Price(s) per share  Volume(s)
     16p                                                                       6,099,135

 d.  Aggregated information

     -       Volume

     -       Price
 e.  Date of the transaction                                      17 December 2024
 f.  Place of the transaction                                     London

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFELFFSELSEDE